Nkarta Inc Ordinary Shares NKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
Nkarta to Participate in September Investor Conferences
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Trading Information
- Previous Close Price
- $1.12
- Day Range
- $1.12–1.21
- 52-Week Range
- $1.11–3.71
- Bid/Ask
- $1.12 / $1.14
- Shares Outstanding
- 71.62M
- Market Cap
- $81.18M
- Volume/Avg
- 1M / 996,149
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 103
- Website
- https://www.nkartatx.com
Valuation
Metric | NKTX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.37 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | NKTX |
|---|---|
Quick Ratio | 5.58 |
Current Ratio | 5.79 |
Interest Coverage | — |
Quick Ratio
NKTX
Profitability
Metric | NKTX |
|---|---|
Return on Assets (Normalized) | −30.68% |
Return on Equity (Normalized) | −40.55% |
Return on Invested Capital (Normalized) | −35.09% |
Return on Assets
NKTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|@g?b>d | LOCK|vYF@ | $132B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|nhX??Mj | LOCK|v&J^ | $96B | |||
| Moderna Inc MRNA | LOCK|###^Yb% | LOCK|%K | $81B | |||
| argenx SE ADR ARGX | LOCK|rVn@rM | LOCK|&?k | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|%G$#@Y | LOCK|!$ | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|KBmcMnY@ | LOCK|nX^$X | $30B | |||
| Incyte Corp INCY | LOCK|JKH%#b | LOCK|qr | $24B | |||
| BioNTech SE ADR BNTX | LOCK|H>wD@! | LOCK|G?! | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|^^zK!^f | LOCK|g^M@x | $20B | |||
| BridgeBio Pharma Inc BBIO | LOCK|^C!$CF | LOCK|?T | $15B |